OBJECTIVE: The primary objective of this study was to assess the use of moxonidine, a centrally acting anti-hypertensive agent in real world practice. MATERIAL AND METHODS: Patients who attended out-patients clinic with diagnosis of hypertension were enrolled in the study. Demographics with co-morbid illnesses of all patients were recorded. Patient's prescriptions were recorded and anti-hypertensive medications were also analysed. RESULTS: A total of 990 patients were eligible during the study period. Moxonidine was used in 4.54% of patients. Two groups could be identified in moxonidine users - one Group with resistant hypertension (30 patients, 3.03% of total, 66.66% of moxonidine users) on multiple drugs to control BP and another Group with intolerance to conventional, first line drugs (15 patients 1.51% of total, 33.33% of moxonidine users). Moxonidine was not used in newly diagnosed hypertension cases. Resistant hypertension and renal failure predicted the use of moxonidine. Majority of drug used was as per current guidelines. CONCLUSIONS: Our study results reflected real world practice of current anti-hypertensive therapy. Patients generally receive medications in accordance with current recommendations and guidelines. Small but significant proportion of patients may require use of drugs like moxonidine to control high BP. Guidelines need to incorporate these real world practices.
OBJECTIVE: The primary objective of this study was to assess the use of moxonidine, a centrally acting anti-hypertensive agent in real world practice. MATERIAL AND METHODS:Patients who attended out-patients clinic with diagnosis of hypertension were enrolled in the study. Demographics with co-morbid illnesses of all patients were recorded. Patient's prescriptions were recorded and anti-hypertensive medications were also analysed. RESULTS: A total of 990 patients were eligible during the study period. Moxonidine was used in 4.54% of patients. Two groups could be identified in moxonidine users - one Group with resistant hypertension (30 patients, 3.03% of total, 66.66% of moxonidine users) on multiple drugs to control BP and another Group with intolerance to conventional, first line drugs (15 patients 1.51% of total, 33.33% of moxonidine users). Moxonidine was not used in newly diagnosed hypertension cases. Resistant hypertension and renal failure predicted the use of moxonidine. Majority of drug used was as per current guidelines. CONCLUSIONS: Our study results reflected real world practice of current anti-hypertensive therapy. Patients generally receive medications in accordance with current recommendations and guidelines. Small but significant proportion of patients may require use of drugs like moxonidine to control high BP. Guidelines need to incorporate these real world practices.
Authors: Michiel J B Kemme; Jeroen P vd Post; Rik C Schoemaker; Matthias Straub; Adam F Cohen; Joop M A van Gerven Journal: Br J Clin Pharmacol Date: 2003-06 Impact factor: 4.335
Authors: F Turnbull; B Neal; T Ninomiya; C Algert; H Arima; F Barzi; C Bulpitt; J Chalmers; R Fagard; A Gleason; S Heritier; N Li; V Perkovic; M Woodward; S MacMahon Journal: BMJ Date: 2008-05-14
Authors: Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He Journal: Lancet Date: 2005 Jan 15-21 Impact factor: 79.321